This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cubist, Optimer, Trius: Antibiotic Deal Making On Tap

LEXINGTON, Mass. ( TheStreet) -- The market loves mergers and acquisition rumors and recently, investors have been chattering a lot about Cubist Pharmaceuticals (CBST) and Optimer Pharmaceuticals (OPTR).

Even before Optimer put itself up for sale earlier this year, Cubist reportedly made an unsolicited $1 billion bid for the company, according to media reports. The rationale for Cubist buying Optimer is fairly easy to understand. The companies are already partners in the co-promotion of Optimer's antibiotic Dificid. Buying Optimer would also help Cubist achieve its five-year strategic goals, one of which is to grow revenue to $2 billion annually.

That being said, I'm not sure Cubist and Optimer make a good strategic fit. For one thing, both companies are developing overlapping antibiotics. Optimer's Dificid is approved for the treatment of C. diff-associated diarrhea (CDAD), while Cubist recently announced plans to move its own C. diff antibiotic surotomycin into phase III studies. Adding Dificid might bolster Cubist revenue in the U.S. but it could also potentially make it more difficult to market surotomycin, if the drug is approved. And Optimer only has U.S. rights to Dificid, meaning Cubist would be unable to sell the drug in Europe.

Cubist may be more interested in acquiring late-stage products that do not overlap with its existing pipeline. Cempra (CEMP - Get Report) and Trius Therapeutics (TSRX) have both been mentioned as possible buyout targets for Cubist. Trius' lead antibiotic tedizolid does overlap to some extent with Cubist's biggest-selling antibiotic Cubicin in the gram-positive bacteria market, although tedizolid has the potential to be used in broader treatment settings.

What has really sparked investor interest, however, is the recent Trius announcement of a new patent allowance for a "therapeutic combination of the experimental medicine tedizolid phosphate with a currently available antibiotic daptomycin." [Daptomycin is the scientific name for Cubicin.]

A fixed-dose combination of tedizolid and Cubicin could limit the small but growing problem of Cubicin resistance and therefore be good for patients. From an investment perspective, the combination of the two drugs is equally positive because it might allow Cubist to protect Cubicin revenue even after patents expire starting in 2018. While the combination would likely not receive New Chemical Entity status given that both drugs would be already approved, Cubist could receive up to five years of market exclusivity if tedizolid-Cubicin is deemed a therapy for a qualified infectious disease.

I'm not guaranteeing a Cubist acquisition of Trius, despite the positive synergies. The two companies may choose to become partners, just like Cubist did with Optimer, or they may do nothing at all. I do believe, however, that deal-making activity will increase between developers and marketers of antibiotics. Cubist, in particular, has been clear about wanting to grow revenue and it's my belief the company needs to look outside for that growth. Trius has already announced plans to find a European partner for tedizolid and Cempra recently brought on a Japanese partner for its antibiotic solithromycin.

An uptick in antibiotic deal making has already started.

Sobek is long Trius.
David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TSRX $0.00 0.00%
OPTR $0.00 0.00%
CBST $101.94 0.14%
CEMP $16.10 0.00%
AAPL $94.19 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs